Ignite Creation Date:
2024-10-26 @ 3:39 PM
Last Modification Date:
2024-10-26 @ 3:39 PM
Study NCT ID:
NCT06574568
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-08-26
Brief Title:
A Study of YKST02 in Participants with Relapsed or Refractory Multiple Myeloma
Sponsor:
None
Organization:
None
Study Overview
Official Title:
A Multicenter Open-label Phase I Study to Evaluate the Safety Tolerability Pharmacokinetics and Preliminary Antitumor Efficacy of YKST02 in Participants with Relapsed or Refractory Multiple Myeloma
Status:
RECRUITING
Status Verified Date:
2024-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study aims to provide a basis for further clinical development of YKST02 YKST02 is a study medicine that targets multiple myeloma and activates the human body to fight against this disease
Detailed Description:
This study is the first-in-human clinical trial to evaluate the safety tolerability pharmacokinetic PK profile and preliminary efficacy of YKST02 in patients with relapsed or refractory multiple myeloma MM Multiple Myeloma MM is a cancer of the bloods plasma cells blood cell YKST02 is a bispecific antibody bridging CD3-expressing T cells and BCMA-expressing multiple myeloma cells to induce T cells-mediated cytotoxicity This study consists of dose escalation phase and dose expansion phase
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None